Posted by Michael Wonder on 04 Jan 2021
US FDA accepts regulatory submission from Pfizer and OPKO for review of somatrogon to treat pediatric patients with growth hormone deficiency
4 January 2020 - If approved, somatrogon will serve as a once-weekly treatment option.
Pfizer and OPKO Health announced today that the US FDA has accepted for filing the initial biologics license application for somatrogon, a long-acting human growth hormone that is intended to be administered once weekly for the treatment of paediatric patients with growth hormone deficiency.
